202 related articles for article (PubMed ID: 27693635)
21. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
Ghiringhelli F; Menard C; Puig PE; Ladoire S; Roux S; Martin F; Solary E; Le Cesne A; Zitvogel L; Chauffert B
Cancer Immunol Immunother; 2007 May; 56(5):641-8. PubMed ID: 16960692
[TBL] [Abstract][Full Text] [Related]
22. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway.
Zhong H; Lai Y; Zhang R; Daoud A; Feng Q; Zhou J; Shang J
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023984
[TBL] [Abstract][Full Text] [Related]
23. Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide.
Setyo L; Ma M; Bunn T; Wyatt K; Wang P
Vet Comp Oncol; 2017 Dec; 15(4):1468-1478. PubMed ID: 28194917
[TBL] [Abstract][Full Text] [Related]
24. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors.
Spugnini EP; Buglioni S; Carocci F; Francesco M; Vincenzi B; Fanciulli M; Fais S
J Transl Med; 2014 Aug; 12():225. PubMed ID: 25143012
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas.
Mainetti LE; Rico MJ; Fernández-Zenobi MV; Perroud HA; Roggero EA; Rozados VR; Scharovsky OG
Ann Oncol; 2013 Sep; 24(9):2310-6. PubMed ID: 23666914
[TBL] [Abstract][Full Text] [Related]
26. In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas.
Shibata MA; Ito Y; Morimoto J; Kusakabe K; Yoshinaka R; Otsuki Y
J Gene Med; 2006 Mar; 8(3):335-52. PubMed ID: 16345101
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Podrazil M; Horvath R; Becht E; Rozkova D; Bilkova P; Sochorova K; Hromadkova H; Kayserova J; Vavrova K; Lastovicka J; Vrabcova P; Kubackova K; Gasova Z; Jarolim L; Babjuk M; Spisek R; Bartunkova J; Fucikova J
Oncotarget; 2015 Jul; 6(20):18192-205. PubMed ID: 26078335
[TBL] [Abstract][Full Text] [Related]
28. Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide.
Polton G; Finotello R; Sabattini S; Rossi F; Laganga P; Vasconi ME; Barbanera A; Stiborova K; Rohrer Bley C; Marconato L
Vet Comp Oncol; 2018 Sep; 16(3):399-408. PubMed ID: 29508493
[TBL] [Abstract][Full Text] [Related]
29. Incidence of sterile hemorrhagic cystitis in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide: 55 cases (2009-2015).
Chan CM; Frimberger AE; Moore AS
J Am Vet Med Assoc; 2016 Dec; 249(12):1408-1414. PubMed ID: 27901449
[TBL] [Abstract][Full Text] [Related]
30. Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles.
Chou PC; Chuang TF; Jan TR; Gion HC; Huang YC; Lei HJ; Chen WY; Chu RM
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):25-34. PubMed ID: 19200609
[TBL] [Abstract][Full Text] [Related]
31. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
Penel N; Adenis A; Bocci G
Crit Rev Oncol Hematol; 2012 Apr; 82(1):40-50. PubMed ID: 21641231
[TBL] [Abstract][Full Text] [Related]
32. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
33. Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma.
Malvicini M; Fiore E; Ghiaccio V; Piccioni F; Rizzo M; Olmedo Bonadeo L; García M; Rodríguez M; Bayo J; Peixoto E; Atorrasagasti C; Alaniz L; Aquino J; Matar P; Mazzolini G
Mol Ther; 2015 Sep; 23(9):1444-55. PubMed ID: 26105158
[TBL] [Abstract][Full Text] [Related]
34. Genetic immunotherapy for cancer.
Elmslie RE; Dow SW
Semin Vet Med Surg Small Anim; 1997 Aug; 12(3):193-205. PubMed ID: 9283245
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer.
Tamura T; Nishi T; Goto T; Takeshima H; Dev SB; Ushio Y; Sakata T
Hum Gene Ther; 2001 Jul; 12(10):1265-76. PubMed ID: 11440620
[TBL] [Abstract][Full Text] [Related]
36. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
37. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.
Jia L; Waxman DJ
Cancer Lett; 2013 Apr; 330(2):241-9. PubMed ID: 23228633
[TBL] [Abstract][Full Text] [Related]
38. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer.
Perroud HA; Rico MJ; Alasino CM; Pezzotto SM; Rozados VR; Scharovsky OG
Indian J Cancer; 2013; 50(2):115-21. PubMed ID: 23979202
[TBL] [Abstract][Full Text] [Related]
39. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.
Naganuma Y; Choijamts B; Shirota K; Nakajima K; Ogata S; Miyamoto S; Kawarabayashi T; Emoto M
Cancer Sci; 2011 Aug; 102(8):1545-52. PubMed ID: 21631643
[TBL] [Abstract][Full Text] [Related]
40. The role of VEGF and other parameters in tracking the clinical course in metronomic chemotherapy.
Ekinci D; Kargi A; Yalcin AD; Savas B
J BUON; 2013; 18(1):245-52. PubMed ID: 23613412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
